Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD. Pioglitazone is metabolized by multiple cytochrome P450 (CYP...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2018/9568269 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550635905482752 |
|---|---|
| author | Hwa Young Ahn Hwan Hee Kim Ji-Yeon Hwang Changhun Park Bo Youn Cho Young Joo Park |
| author_facet | Hwa Young Ahn Hwan Hee Kim Ji-Yeon Hwang Changhun Park Bo Youn Cho Young Joo Park |
| author_sort | Hwa Young Ahn |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD. Pioglitazone is metabolized by multiple cytochrome P450 (CYP) enzymes, which are regulated by the xenobiotic receptor constitutive androstane receptor (CAR). In this study, we investigated the effects of pioglitazone on NAFLD by absence of CAR activity under high-fat (HF)-fed conditions. CAR-/- mice showed significant improvement in NALFD after 12 weeks of pioglitazone treatment compared to wild-type mice. This improvement in NAFLD persisted in CAR-/- mice regardless of blood pioglitazone concentration. The expression of lipogenesis genes in the liver, sterol-regulatory element binding protein-1c (SREBP-1c), and stearoyl-CoA desaturase (SCD)-1 was decreased after pioglitazone treatment in HF-fed CAR-/- mice. In addition, the expression of peroxisome proliferator-activated receptor gamma 2 (PPARγ2) was decreased by pioglitazone in HF-fed CAR-/- mice. Changes in SREBP-1c and PPAR γ2 remained constant over short-term (6 h) pioglitazone and lipid injection. Our results showed that NAFLD was improved significantly by pioglitazone in a CAR deletion state. These results might be valuable because they suggest that interaction with CAR and pioglitazone/PPARγ2 may be important in regulating gene expression associated with NAFLD. |
| format | Article |
| id | doaj-art-82e76e0f924745b3ae56736ad099f561 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-82e76e0f924745b3ae56736ad099f5612025-02-03T06:06:12ZengWileyPPAR Research1687-47571687-47652018-01-01201810.1155/2018/95682699568269Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor ExpressionHwa Young Ahn0Hwan Hee Kim1Ji-Yeon Hwang2Changhun Park3Bo Youn Cho4Young Joo Park5Department of Internal Medicine, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of KoreaSeoul National University Hospital Biomedical Research Institute, 101, Daehak-ro, Jongno-gu, Seoul 03080, Republic of KoreaPreclinical Experimental Center, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of KoreaClinical Trials Center, Severance Hospital, Yonsei University Health System, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of KoreaDepartment of Internal Medicine, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of KoreaSeoul National University Hospital Biomedical Research Institute, 101, Daehak-ro, Jongno-gu, Seoul 03080, Republic of KoreaNonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD. Pioglitazone is metabolized by multiple cytochrome P450 (CYP) enzymes, which are regulated by the xenobiotic receptor constitutive androstane receptor (CAR). In this study, we investigated the effects of pioglitazone on NAFLD by absence of CAR activity under high-fat (HF)-fed conditions. CAR-/- mice showed significant improvement in NALFD after 12 weeks of pioglitazone treatment compared to wild-type mice. This improvement in NAFLD persisted in CAR-/- mice regardless of blood pioglitazone concentration. The expression of lipogenesis genes in the liver, sterol-regulatory element binding protein-1c (SREBP-1c), and stearoyl-CoA desaturase (SCD)-1 was decreased after pioglitazone treatment in HF-fed CAR-/- mice. In addition, the expression of peroxisome proliferator-activated receptor gamma 2 (PPARγ2) was decreased by pioglitazone in HF-fed CAR-/- mice. Changes in SREBP-1c and PPAR γ2 remained constant over short-term (6 h) pioglitazone and lipid injection. Our results showed that NAFLD was improved significantly by pioglitazone in a CAR deletion state. These results might be valuable because they suggest that interaction with CAR and pioglitazone/PPARγ2 may be important in regulating gene expression associated with NAFLD.http://dx.doi.org/10.1155/2018/9568269 |
| spellingShingle | Hwa Young Ahn Hwan Hee Kim Ji-Yeon Hwang Changhun Park Bo Youn Cho Young Joo Park Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression PPAR Research |
| title | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| title_full | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| title_fullStr | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| title_full_unstemmed | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| title_short | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| title_sort | effects of pioglitazone on nonalcoholic fatty liver disease in the absence of constitutive androstane receptor expression |
| url | http://dx.doi.org/10.1155/2018/9568269 |
| work_keys_str_mv | AT hwayoungahn effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression AT hwanheekim effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression AT jiyeonhwang effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression AT changhunpark effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression AT boyouncho effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression AT youngjoopark effectsofpioglitazoneonnonalcoholicfattyliverdiseaseintheabsenceofconstitutiveandrostanereceptorexpression |